<https://rdf.molmedb.upol.cz/reference/ref1970> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM475912>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2007.05.019"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/pmid> "17531480"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21>;
	<http://purl.org/dc/terms/bibliographicCitation> "Sandham DA, Aldcroft C, Baettig U, Barker L, Beer D, Bhalay G, Brown Z, Dubois G, Budd D, Bidlake L, Campbell E, Cox B, Everatt B, Harrison D, Leblanc CJ, Manini J, Profit R, Stringer R, Thompson KS, Turner KL, Tweed MF, Walker C, Watson SJ, Whitebread S, Willis J, Williams G, Wilson C.: 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett, Volume 17 (15), 2007"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1023790> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref1970> .
<https://rdf.molmedb.upol.cz/interaction/int977768> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref1970> .
<https://rdf.molmedb.upol.cz/interaction/int977270> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref1970> .
<https://rdf.molmedb.upol.cz/interaction/int1023789> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref1970> .